-
Mashup Score: 4Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial - 1 year(s) ago
In patients with oligometastatic renal cell carcinoma, radiotherapy to all metastases followed by short-course pembrolizumab is safe, with a grade 3 adverse event rate of 13%. The combination is effective, with median progression-free survival of 15.6 mo and 2-yr local control of 92%.
Source: European UrologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data - 1 year(s) ago
This study shows no effect of enzalutamide on hospitalized COVID-19 patients or a decrease in the risk of COVID-19 severity from any androgen-inhibiting drug in the population. Collectively, there is evidence of no beneficial role of androgen inhibition in COVID-19.
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
Congratulations to Karen Welén on being awarded the European Urology Best Scientific Paper on Fundamental Research 2023. Dr. Welén collected her award alongside her co-author, Andreas Josefsson. Read the paper here: https://t.co/fZvE3lNYdm @And_josefsson #EAU23 #Medtwitter https://t.co/tphzGJ5guC
-
-
Mashup Score: 2Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial - 1 year(s) ago
In patients with oligometastatic renal cell carcinoma, radiotherapy to all metastases followed by short-course pembrolizumab is safe, with a grade 3 adverse event rate of 13%. The combination is effective, with median progression-free survival of 15.6 mo and 2-yr local control of 92%.
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
@_ShankarSiva @declangmurphy @PeterMacCC Read the article here: https://t.co/WB7RKUfaYK
-
-
Mashup Score: 2Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer - 1 year(s) ago
Multiparametric magnetic resonance imaging (MRI) alone misses a considerable percentage of clinically significant prostate cancers (Gleason grade group ≥2) among men on active surveillance for low-risk prostate cancer. We conclude that MRI alone cannot safely replace surveillance prostate biopsies, particularly at confirmatory biopsy or in the presence of other risk factors.
Source: European UrologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Great debate @mrsprostate @Albert0Briganti at #eau23: can we follow men on AS with MRI alone? I might suggest truth is in the middle: confirmatory bx is essential but MRI NPV rises downstream https://t.co/Fr0OZHPenZ @EUplatinum @CChuMD https://t.co/l0e1y0zA7P
-
-
Mashup Score: 0
We examined the relevance of the National Comprehensive Cancer Network (NCCN) very low risk classification for prostate cancer in the modern era. In a large active surveillance cohort of 1276 patients, we show that no men diagnosed after 2018 satisfied the criteria for NCCN very low risk.
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
Shee et al: Limited Relevance of the VLR PCa Classification in the Modern Era: Results from a Large Institutional AS Cohort https://t.co/D04Amj3YuU "NCCN VLR criteria are less applicable in the targeted bx era; CAPRA score is a better contemporary risk strat tool for men on AS" https://t.co/BlAXvjZ1Gs
-
-
Mashup Score: 4
We analyzed disease-free survival by tumor cell score and combined positive score for PD-L1 expression in CheckMate 274. The results provide insights into the role of adjuvant nivolumab in patients with muscle-invasive urothelial carcinoma who have low PD-L1 expression according to tumor cell score.
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
DFS Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 CPS and Tumor Cell Score https://t.co/ctkDCB6QUq "Patients with CPS ≥1 experienced improved DFS with nivolumab (HR 0.50, 95% CI 0.35–0.71)" https://t.co/fdbUW9U94m
-
-
Mashup Score: 0Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer - 1 year(s) ago
We assessed mutations in ERCC2, ERBB2, and ATM/RB1/FANCC as predictors of pathological response to neoadjuvant chemotherapy in bladder cancer. We confirmed an association of ERCC2 mutations with pathological response, but not with complete response, overall survival, or recurrence-free survival. Alterations in ERBB2 or ATM/RB1/FANCC were not predictive.
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
Articles in Press: Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer https://t.co/YUvsTTxiub @CuriousDrKris @MariaJRibal @AntonioAlcarazA @Roland3097 @JLWrightMD @loumengual @joostboormans @pcvblack https://t.co/q5z2k8aEeG
-
-
Mashup Score: 0
Flexible parametric survival models with cure and milestone survival complement the Cox model, and help clinicians and regulators evaluate the benefit-risk ratios of new therapeutics. The flexible parametric survival model with cure facilitates patients’ understanding of risk information.
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials https://t.co/xlLiFFiLYw @PouesselD @HouedeNadine @PrDelord https://t.co/QUeBxRoT5x
-
-
Mashup Score: 0
Robot-assisted radical prostatectomy (RARP) offers enhanced manipulation and potentially tremor filtration in comparison to an open approach [1], and positive clinical outcomes have been reported [2,3]. Different surgical robots are currently available, with the da Vinci still holding a dominant market position [4]. However, surgical robots are costly and difficulties can arise in adoption in…
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
New Research Letter from Dominik Böhlen Rolf Gerber First Ever Radical Prostatectomy Performed with the New Dexter Robotic System™ https://t.co/nqmarpNRfp https://t.co/a8lpseqMFZ
-
-
Mashup Score: 0
The Prostate Cancer Patient Empowerment Program (PC-PEP), a multidimensional, online, home-based 6-mo empowerment program, improves mental health among men scheduled for prostate cancer surgery or radiotherapy compared with standard of care. PCPEP.org is cost effective, convenient for clinicians, and addresses side effects and the high rates of depression and anxiety among prostate cancer…
Source: European UrologyCategories: Latest Headlines, UrologyTweet-
A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial https://t.co/fD3lMb1Vj5 @GabrielaIDr et al https://t.co/Ajng2mqd8L
-
RT @EUplatinum: @_ShankarSiva @declangmurphy @PeterMacCC Read the article here: https://t.co/WB7RKUfaYK